食管癌患者接受放化疗后并发心包积液的风险因素。

Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.

机构信息

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Anticancer Res. 2014 Dec;34(12):7389-93.

PMID:25503178

Abstract

AIM

We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy.

PATIENTS AND METHODS

Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed.

RESULTS

The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE.

CONCLUSION

The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.

摘要

目的

我们研究了影响接受根治性放化疗的 I 期食管癌患者发生心包积液（PCE）风险的临床和剂量学因素。

患者和方法

回顾性分析了 69 例接受根治性放化疗的 I 期食管癌患者。治疗包括三维适形放疗（60 Gy，30 次）联合化疗。分析了与 PCE 发展相关的临床和剂量学因素。

结果

中位随访时间为 37 个月（范围=8-111 个月）；粗 PCE 发生率为 52.2%。2 级和 3 级发生率分别为 47.8%和 4.3%。放疗后 PCE 发病的中位时间为 5.7 个月。多因素分析显示，心包 V30≥41.6%、年龄≥66 岁、BMI≥19 和糖尿病（DM）是发生 PCE 的显著预测因素。